勒维体痴呆症 - 一个临床病理学更新
János Bencze1,2, Woosung Seo3, Abdul Hye4,5
1Department of Pathology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Free neuropathology
|June 7, 2023
概括
勒维体痴呆症 (DLB) 是一种进展性神经退行性疾病,其特征是勒维体. 本次审查涵盖了DLB的情况.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 病理学 病理学 病理学
背景情况:
- 痴呆症代表着一个重大的全球健康挑战,痴呆症与勒维体 (DLB) 是一个常见的形式.
- DLB的特征是细胞内Lewy体 (LB) 和Lewy神经元 (LN),主要由聚合的α-synuclein组成,将其归类为α-synucleinopathy.
- 在DLB中,认知和运动缺陷源于LB和LN沉积物在中枢神经系统的特定位置.
研究的目的:
- 系统地审查DLB的病因学,流行病学和病理特征.
- 探索DLB的成像发现和临床病理相关性.
- 总结目前的诊断标准和DLB的新兴治疗策略,包括阿尔茨海默病 (AD) 的差异诊断.
主要方法:
- 系统的文献审查.
- 神经病理学特征的分析 (宏观和微观).
- 对结构和功能神经成像发现的审查.
- 检查临床病理相关性.
- 综合诊断标准和治疗方法.
主要成果:
- DLB病理涉及勒维体和神经细胞中的α-synuclein聚合.
- 临床病理相关性将病变位置与特定症状联系起来.
- 由于频繁的共同病理,对阿尔茨海默氏症的差异诊断至关重要.
结论:
- 尽管目前存在知识差距,但诊断和研究工具的进步为改善DLB管理提供了希望.
- 更好地了解DLB病因,病理和临床表现至关重要.
- 未来的研究应该专注于改进诊断准确性和开发有效的治疗方法,以改善患者的生活质量.
更多相关视频
08:29Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
Published on: December 18, 2016
14.1K
10:03Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
Published on: August 16, 2020
10.7K
相关概念视频
01:15Parkinson's Disease: Overview
612
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
612
01:30Dementia
143
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
143
01:26Alzheimer's Disease: Overview
536
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
536
01:22Lysosomal Hydrolases
3.9K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.9K
01:22Alzheimer's Disease: Treatment
224
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
224
01:24Parkinson's Disease: Treatment
305
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
305